Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2189 • 2012 ACR/ARHP Annual Meeting
Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjögren’s Syndrome: Results of the Beliss Study
Salvatore De Vita¹, Raphaèle Seror², Luca Quartuccio³, Frederic Desmoulins⁴, Sara Salvin⁵, Gabriel Baron⁶, Martina Fabris⁷, Philippe Ravaud⁸, Miriam Isola⁹ and Xavier Mariette¹⁰, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, LE Kremlin-Bicetre, France, ³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁵Rheumatology Clinic, DSMB, University of Udine,, Udine, Italy, ⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ⁷Institute of Clinical Pathology, Udine, Italy, ⁸Epidemiology, Université Paris-Descartes, Paris, Paris, France, ⁹Institute of Statistics, DSMB, University of Udine, Udine, Italy, ¹⁰Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: to report the effects of anti-BAFF/BLyS antibody belimumab (BEL) on the different ogan manifestations of primary Sjögren’s syndrome (pSS), by evaluating the ESSDAI score…
Abstract Number: 519 • 2012 ACR/ARHP Annual Meeting
Sex-Specific Regulatory T Cell Dysfunction in a Mouse Model of Sjögren Syndrome
Scott M. Lieberman¹, Portia A. Kreiger² and Gary A. Koretzky³, ¹Pediatrics, Div Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pathology, Nemours/A.I. DuPont Hospital for Children, Wilmington, DE, ³Medicine, University Pennsylvania, Philadelphia, PA
Background/Purpose: CD4+Foxp3+ regulatory T cells (Tregs) are a specialized population of lymphocytes which prevent autoimmunity in normal hosts. Treg dysfunction has been implicated in autoimmunity; however results…
Abstract Number: 2673 • 2012 ACR/ARHP Annual Meeting
Sibling Relative Risk and Heritability of Sjögren’s Syndrome: A Nationwide Population Study in Taiwan
Chang-Fu Kuo¹, Matthew J. Grainge², Kuang-Hui Yu³, Lai-Chu See⁴, Shue-Fen Luo³, Ana M. Valdes⁵, I-Jun Chou⁶, Hsiao-Chun Chang³, Weiya Zhang¹ and Michael Doherty⁷, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁴Department of Public Health, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Although familial aggregation has been found in many autoimmune diseases, the evidence for familial aggregation in Sjögren’s syndrome is lacking. The aims of this…
Abstract Number: 2190 • 2012 ACR/ARHP Annual Meeting
Antimalarials for Sjogren’s Syndrome Treatment in Adults, Meta-Analysis
Vibian A. Coy¹, Carlos E. Granados², Diana Gil¹, Alejandro Junca¹, Daniel Jaramillo¹, Antonio A. Iglesias-Gamarra³, Jose Felix Restrepo⁴ and Federico Rondon-Herrera⁴, ¹Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Fellow of Rheumatology Universidad Nacional de Colombia, Bogotá, Colombia, ²Departamento de Medicina, facultad de medicina, Professor -Universidad Nacional de Colombia, Bogotá, Colombia, ³Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor-Universidad Nacional de Colombia, Bogota, Colombia, ⁴Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor -Universidad Nacional de Colombia, Bogota, Colombia
Background/Purpose: Sjögren´s syndrome (SS) is a chronic inflammatory autoimmune disease that is presented with lymphocytic infiltration of exocrine glands. Its secondary secretory dysfunction may involved…
Abstract Number: 521 • 2012 ACR/ARHP Annual Meeting
Differences in Genome-Wide DNA Methylation Profiles Across Multiple Cell and Tissue Types in Sjögren’s Syndrome (SS)
Lindsey A. Criswell¹, Diana Quach², Hong L. Quach², Emon Elboudwarej² and Lisa F. Barcellos², ¹Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ²Epidemiology, University of California, Berkeley, Berkeley, CA
Background/Purpose: Increasing evidence supports a role for epigenetic factors, including DNA methylation status, in autoimmune disease risk and severity. Our goal is to characterize DNA…
Abstract Number: 2674 • 2012 ACR/ARHP Annual Meeting
Cis-Expression Quantitative Trait Loci Analysis of Dysregulated Interferon-Pathway Genes Identifies HLA-C and OAS1 As Novel Candidates for Susceptibility to Sjögren’s Syndrome
He Li¹, John A. Ice², Jennifer A. Kelly³, Indra Adrianto², Stuart B. Glenn⁴, Kimberly S. Hefner⁵, Evan G. Vista⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, Glen D. Houston⁹, David M. Lewis¹⁰, Michael Rohrer⁸, Pamela Hughes⁸, John B. Harley¹¹, Courtney G. Montgomery², James Chodosh⁷, James A. Lessard¹², Juan-Manuel Anaya¹³, Barbara M. Segal¹⁴, Nelson L. Rhodus¹⁵, Lida Radfar¹⁶, Mark B. Frank¹⁷, R. Hal Scofield¹⁸, Christopher J. Lessard¹⁹ and Kathy Moser Sivils³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁷Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Valley Bone and Joint Clinic, Grand Forks, ND, ¹³School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of Europeans. Dysregulation of interferon…
Abstract Number: 2191 • 2012 ACR/ARHP Annual Meeting
Secretagogue Use in Patients with Primary Sjogren’s Syndrome
Ghaith Noaiseh¹, Joshua Baker² and Frederick B. Vivino³, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Medicine, Penn Presbyt Med Ctr, Philadelphia, PA
Background/Purpose: Secretagogues are commonly used to treat xerostomia in primary Sjogren’s syndrome (pSS). Side effects and/or lack of efficacy sometimes result in cessation of…
Abstract Number: 522 • 2012 ACR/ARHP Annual Meeting
Genetic Variation in the NCR3 Locus Is Associated with Anti-SSA⁄SSB Positive Primary Sjögren′s Syndrome in Scandinavian Samples
Gunnel Nordmark¹, Maija-Leena Eloranta¹, Per Eriksson², Elke Theander³, Helena Forsblad-d'Elia⁴, Roald Omdal⁵, Marie Wahren-Herlenius⁶, Roland Jonsson⁷ and Lars Rönnblom¹, ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Dept of Rheumatology, Skane University Hospital, Lund University, Malmö, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Department of Internal Medicine, Stavanger university Hospital, Stavanger, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁶Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway
Background/Purpose: Candidate gene studies in primary Sjögren’s syndrome (pSS) have identified polymorphisms in genes involved in the type I interferon (IFN) system and the type…
Abstract Number: 2675 • 2012 ACR/ARHP Annual Meeting
Oral and Gut Microbiota Influence Immune Responses to Sjogren’s Syndrome Associated Antigen Ro60
Agnieszka Szymula¹, Barbara Szczerba¹, Harini Bagavant¹, Shu-Man Fu² and Umesh Deshmukh³, ¹Department of Medicine, University of Virginia, Charlottesville, VA, ²University of Virginia, Charlottesville, VA, ³Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: Autoantibodies reactive against Ro60 protein are often found in patients with Sjogren’s syndrome. This study was undertaken to investigate the role of oral and…
Abstract Number: 2192 • 2012 ACR/ARHP Annual Meeting
Phenotypic Features of Sjögren’s Syndrome Among Patients with Low-Titer SSA/B Antibodies
Mara McAdams DeMarco¹, Mi Y. Lam², Stephen Shiboski², Lindsey A. Criswell³, Caroline Shiboski⁴ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The significance of a low titer of SSA and/or SSB antibodies (SSA/B-Ab) in individuals with clinical or other laboratory findings suggestive of Sjögren’s syndrome…
Abstract Number: 523 • 2012 ACR/ARHP Annual Meeting
Use of Global Gene Expression Profiling to Characterize Sjögren’s Patients Who Underexpress Interferon-Inducible Genes
John A. Ice¹, He Li², Jennifer A. Kelly¹, Indra Adrianto¹, Stuart B. Glenn³, Kimberly S. Hefner⁴, Evan G. Vista⁵, Donald U. Stone⁶, Raj Gopalakrishnan⁷, Glen D. Houston⁸, David M. Lewis⁹, Michael Rohrer⁷, Pamela Hughes⁷, John B. Harley¹⁰, Courtney G. Montgomery¹¹, James Chodosh¹², James A. Lessard¹³, Juan-Manuel Anaya¹⁴, Barbara M. Segal¹⁵, Nelson L. Rhodus¹⁶, Lida Radfar¹⁷, Mark B. Frank¹, R. Hal Scofield¹⁸, Christopher J. Lessard¹⁹ and Kathy Moser Sivils¹, ¹Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁵Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁶Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁸Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹³Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁴School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹⁵Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth. We previously reported overexpression of interferon-inducible (IFI) genes…
Abstract Number: 2676 • 2012 ACR/ARHP Annual Meeting
Long-Term Humoral Autoimmunity to Ro60 in Primary Sjögren’s Syndrome Is Driven by Clonal Succession
Rhianna Lindop¹, Isabell Bastian¹, Georgia Arentz¹, Lauren Thurgood¹, Andrew Whyte¹, Tim, K. Chataway², Michael Jackson¹ and Tom Gordon¹, ¹Immunology, Flinders Medical Centre and Flinders University, Adelaide, Australia, ²Human Physiology, School of Medicine, Flinders University, Adelaide, Australia
Background/Purpose : Long-lived humoral autoimmunity to Ro60 is considered a hallmark of primary Sjögren’s syndrome (SS), but the mechanism by which this immunity is sustained over…
Abstract Number: 2193 • 2012 ACR/ARHP Annual Meeting
Validity of Low Titers of SSA/B Antibodies in Predicting A Key Feature of Sjögren’s Syndrome
Mara McAdams DeMarco¹, Mi Y. Lam², Stephen Shiboski², Lindsey A. Criswell³, Caroline Shiboski⁴ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The validity of low titers of SSA and/or SSB (SSA/B) antibodies (Ab) in the diagnosis of Sjögren’s syndrome (SS) has not been defined. We…
Abstract Number: 525 • 2012 ACR/ARHP Annual Meeting
Gene Expression Profiling in a Large Cohort of Europeans with Sjögren’s Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-Related Pathways
He Li¹, John A. Ice², Jennifer A. Kelly³, Indra Adrianto², Stuart B. Glenn⁴, Kimberly S. Hefner⁵, Evan G. Vista⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, Glen D. Houston⁹, David M. Lewis¹⁰, Michael Rohrer⁸, Pamela Hughes⁸, John B. Harley¹¹, Courtney G. Montgomery², James Chodosh⁷, James A. Lessard¹², Juan-Manuel Anaya¹³, Barbara M. Segal¹⁴, Nelson L. Rhodus¹⁵, Lida Radfar¹⁶, Mark B. Frank¹⁷, R. Hal Scofield¹⁸, Christopher J. Lessard¹⁹ and Kathy Moser Sivils³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁷Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Valley Bone and Joint Clinic, Grand Forks, ND, ¹³School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS), characterized by lymphocytic infiltration of exocrine glands, is a progressive autoimmune exocrinopathy present in 0.7-1% of Europeans. To better understand the…
Abstract Number: 2197 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of Blood B-Cell Subset Profiling and Autoimmunity Markers in Anti-SSA-Negative Sjögren’s Syndrome Patients
Divi Cornec¹, Alain Saraux², Jacques-Olivier Pers³, Sandrine Jousse-Joulin⁴, Yves Renaudineau³, Thierry Marhadour⁵ and Valerie Devauchelle-Pensec⁶, ¹Department of rheumatology, Brest Occidentale University, Brest, France, ²Department of rheumatology and unit of immunology (EA 2216), Brest Occidentale university, Brest, France, ³Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁴Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, ⁵Rheumatology, CHU de la Cavale Blanche, Brest, France, ⁶Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France
Background/Purpose: Recently published ACR classification criteria for primary Sjögren’s syndrome (pSS) suggest considering antinuclear antibodies (ANA) titer and rheumatoid factor (RF) positivity in patients negative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].